Dr. Rosner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Fl 1
Baltimore, MD 21201Phone+1 410-328-2575
Education & Training
- Albert Einstein College of MedicineClass of 2017
Certifications & Licensure
- MD State Medical License 2021 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2024-11-15 - Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?Joshua E Reuss, Samuel Rosner, Benjamin P Levy
Clinical Advances in Hematology & Oncology. 2024-06-01 - 4 citationsElucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R White
Clinical Cancer Research. 2024-01-17
Press Mentions
- Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
- Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung CancerFebruary 15th, 2023
- Neoadjuvant Nivolumab Shows Long-Term Benefit in Patients with Non-Small Cell Lung CancerFebruary 15th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: